Kura Oncology (NASDAQ:KURA) Issues Quarterly Earnings Results, Beats Expectations By $0.43 EPS

Kura Oncology (NASDAQ:KURA) released its quarterly earnings data on Wednesday. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43, Zacks reports.

Kura Oncology Stock Performance

Shares of KURA traded down $0.11 during mid-day trading on Wednesday, hitting $7.77. 693,965 shares of the company’s stock were exchanged, compared to its average volume of 1,618,769. The firm has a market capitalization of $604.23 million, a P/E ratio of -3.29 and a beta of 0.78. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The business’s 50 day moving average is $8.22 and its two-hundred day moving average is $13.96. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Analysts Set New Price Targets

KURA has been the subject of a number of recent analyst reports. JMP Securities reissued a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Bank of America lowered their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. Scotiabank dropped their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Finally, Wedbush lifted their target price on shares of Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 in the last ninety days. Insiders own 5.50% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.